Search research articles
Contact Us
Filters
Showing results (251-260 of 284) with videos related to
Page
of 29
Sort By:
Nature Medicine
|
June 2, 2015
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna, Benedetta Mussolin, Michela Buscarino, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 21, 2020
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer
Claudia Cardone, Bernadette Blauensteiner, Veronica Moreno-Viedma, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 19, 2021
Synaptophysin expression in <sup>V600EBRAF-</sup>mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis
Matteo Fassan, Massimo Milione, Giulia Maddalena, et al.
Nature Medicine
|
September 13, 2022
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF<sup>V600E</sup> metastatic colorectal cancer
Elena Elez, Javier Ros, Jose Fernández, et al.
Cancers
|
July 2, 2021
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study
Alessandra Raimondi, Federica Palermo, Michele Prisciandaro, et al.
Cancers
|
October 14, 2023
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence
Lucio Urbani, Nicolò Roffi, Roberto Moretto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 8, 2022
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O<sup>6</sup>-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial
Federica Morano, Alessandra Raimondi, Filippo Pagani, et al.
Scientific Reports
|
June 20, 2020
Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer
Ana Barat, Dominiek Smeets, Bruce Moran, et al.
The Lancet. Oncology
|
May 31, 2022
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, et al.
Therapeutic Advances in Medical Oncology
|
July 15, 2021
Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis
Jun Yin, Shaheenah Dawood, Romain Cohen, et al.
Page
of 29
Search research articles
Search
Showing results (251-260 of 284) with videos related to
Sort By:
Page
of 29
Nature Medicine
|
June 2, 2015
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna, Benedetta Mussolin, Michela Buscarino, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 21, 2020
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer
Claudia Cardone, Bernadette Blauensteiner, Veronica Moreno-Viedma, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 19, 2021
Synaptophysin expression in <sup>V600EBRAF-</sup>mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis
Matteo Fassan, Massimo Milione, Giulia Maddalena, et al.
Nature Medicine
|
September 13, 2022
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF<sup>V600E</sup> metastatic colorectal cancer
Elena Elez, Javier Ros, Jose Fernández, et al.
Cancers
|
July 2, 2021
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study
Alessandra Raimondi, Federica Palermo, Michele Prisciandaro, et al.
Cancers
|
October 14, 2023
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence
Lucio Urbani, Nicolò Roffi, Roberto Moretto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 8, 2022
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O<sup>6</sup>-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial
Federica Morano, Alessandra Raimondi, Filippo Pagani, et al.
Scientific Reports
|
June 20, 2020
Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer
Ana Barat, Dominiek Smeets, Bruce Moran, et al.
The Lancet. Oncology
|
May 31, 2022
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, et al.
Therapeutic Advances in Medical Oncology
|
July 15, 2021
Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis
Jun Yin, Shaheenah Dawood, Romain Cohen, et al.
Page
of 29